-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Janux Therapeutics, Lowers Price Target to $26

Benzinga·05/08/2026 15:07:11
Listen to the news
Piper Sandler analyst Kelsey Goodwin maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lowers the price target from $30 to $26.